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THE CONCEPT OF PASSENGER LEUKOCYTES AND THEIR ROLE IN 
REJECTION 
L eukocytes or hematolymphoid cells reside. at least temporarily. in 
the interstitium of all organs. These cells are known as "passenger 
leukocytes" when the organ becomes an allograft. because they are car-
ried along with the parenchyma and stroma into the body of the recipi-
ent. Passenger leukocytes are the most immunogenic cells in an allograft 
and function as initiators of the rejection reaction. 1- 3 Steinman and col-
leagues4 - 8 identified a unique cell type that has become the passenger 
leukocyte prototype, the interstitial dendritic cell (DC). It is characterized 
by intense major histocompatibility complex (MHC) class II antigen, co-
stimulatory9 and adhesion molecule expression,lO· 11 and is the most ef-
fective (and perhaps only) stimulator of a mixed lymphocyte reaction 
(MLR).8 
Besides Des, allografts contain many other types of donor leukocytes. 
Their number and phenotypic composition vary with the organ. For ex-
ample, intestine and lung allografts are "leukocyte-rich," and a high per-
centage of the cells are mature T and 8 lymphocytes. Liver allografts are 
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also considered leukocvte-rich, but contain more macrophages, B cells, 
and hematolymphoid progenitor cell populations. By comparison, heart 
and kidney allografts could be considered "leukocyte-poor," but these or-
gans still contain an appreciable number of DCs. 
Since cells normally traffic into and out of organs, some passenger 
leukocytes will emigrate from an allograft into recipient tissues immedi-
ately after transplantation, while others remain in the allograft. This ex-
plains the finding of donor leukocytes in the recipient spleen within 
hours to days after transplantation.12- 14 Unless the donor and recipient 
are HLA-identical, arrival of the donor leukocytes (especially the DCs) in 
the recipient spleen 12-14 and arrival of recipient lymphocytes in DC-rich 
areas of the allograft14. 15 elicit the in vivo equivalent of the in vitro 
MLR.12-14 The former is known as "central sensitization" and the latter 
as "peripheral sensitization." Both are initiation sites of the rejection re-
action that is ultimately directed at the parenchyma and blood vessels of 
solid-organ allografts. 
The scenario just described (i.e., that passenger leukocytes initiate re-
jection) has guided the field of transplantation biology for the last 25 
years. Investigators have therefore attempted to purge passenger leuko-
cytes from donor organs prior to implantation in the expectation of pro-
longing graft survival, or achieving graft acceptance without immunosup-
pressive therapy.16 Although this approach has clearly resulted in im-
proved short-term allograft survival, the allografts depleted of passenger 
leukocytes are still eventually rejected. This finding is consistent with the 
observation that even pure keratinocyte cultures. devoid of all contami-
nating passenger leukocytes, are rejectedY Moreover. even after the pas-
senger leukocytes are destroyed, the allograft is still susceptible to chronic 
rejection. 18 These observations suggest that the above model cannot ad-
equately explain some fundamental observations in transplantation biol-
ogy. 
Batchelor and Braun 19 have more fully developed the above paradigm 
to explain this discrepancy. They suggest that acute rejection is medi-
ated by a distinct set of alloreactive recipient T cells that are directly ac-
tivated after physical contact with donor DCs. The reaction observed in 
vivo is akin to the in vitro MLR. As mentioned above, it occurs both 
within the allograft and in the recipient's lymphoid tissue. It manifests 
as a burst of immune activation, usually occurring during the first few 
weeks after transplantation. In the allograft this reaction is also known as 
acute cellular rejection. and for the most part is easily controlled with 
increased immunosuppression. A period of relative calm follows. when 
the donor passenger leukocytes within the allograft are replaced by re-
cipient cells. The donor cells released from the allograft are thought to 
be destroyed. or simply die out. 
Unfortunately. another distinct set of alloactivated T cells emerges 
that mediate chronic rejection. 19 Host-derived antigen-presenting cells 
process and indirectly present to the recipient immune system donor 
MHC and possibly other antigens shed from the allograft. Theoretically. 
this shedding of foreign epitopes subjects the allograft to indolent but re-
lentless low-grade damage that eventually results in the development of 
obliterative arteriopathy. or chronic rejection. If this form of rejection 
j 
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could be avoided. organ transplantation would become more routine than 
it already is. because a continual decline of allograft function plagues 
most long-term survivors of kidney and heart transplantation, but liver 
allografts are relatively resistant. Later. we explore a possible relationship 
between passenger leukocytes and hepatic resistance to chronic rejection. 
DONOR BONE MARROW CELLS AS TOLEROGENS 
In a separate area of transplantation biology research, investigators have 
shown that donor hematolymphoid cells carry with them the ability to 
render the recipient's immune system specifically unresponsive to sub-
sequent allografts from the same donor. This concept was first uncovered 
by Owen20 in twin cattle fetuses that shared placental circulations. The 
immune systems of the twins were naturally mixed chimeras, or com-
posed of hematolymphoid cells from both individuals. They were able to 
accept organ allografts from each other without the need for immunosup-
pression. Billingham, Brent. and Medawar21 and Main and Prehn22 later 
achieved the same results in adult rodents. by infusing donor bone mar-
row into a recipient whose own immune system had been destroyed by 
irradiation. These animals had fully chimeric immune systems, composed 
exclusively of donor hematolymphoid cells, and they accepted other or-
gans from the same donor without immunosuppression. Unfortunately. 
attack of the defenseless recipient by the donor hematolymphoid cells.23 
or graft-versus-host disease (GVHD), has limited the clinical applicabil-
ity of this approach. 
Because of the early promise of subsequent drug-free allograft accep-
tance. numerous subsequent experimental animal models have pursued 
variations of the irradiation-donor bone marrow infusion protocol. Che-
motherapeutic cytoablation and monoclonal antibody therapy with 
lower-dose or localized irradiation. and donor bone marrow infusion pro-
tocols were successfully developed.23 - 35 
One variation of the induced chimerism approach that has been 
particularly successful in small animals was developed by Ildstad and 
Sachs.36 It also illustrated an important concept. They used conditioning 
irradiation followed by a mixture of both donor and recipient bone mar-
row cells that routinely resulted in mixed allogenic chimeras. These ani-
mals were both tolerant of donor allografts and resistant to GVHD.J6 De-
spite mixed chimeric immune systems, allogenic cell populations were 
able to cooperate and the animals remained healthy and apparently not 
susceptible to disease. More than anything else. the studies just cited have 
shown that specific allogenic tolerance is transferable with donor bone 
marrow; and the persistence of donor hematolymphoid cells is a prereq-
uisite for continued specific nonreactivity. 
Human studies using preconditioning with monoclonal antibody 
therapy and delayed infusion of donor bone marrow given several weeks 
after kidney transplantation have shown some promise. but have fallen 
short of expectations.J7 Although rejection was not completely avoided 
and all of the recipients were not made tolerant. it was encouraging that 
rejection and chimerism were less frequently encountered together in 
long-term survivors. 
.- .. _-----._----_. 
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After successful bone marrow transplantation in humans. the entire 
immune system of the donor is transferred into the recipieneB- 4o similar 
to the fully chimeric model of Main and Prehn.22 Since an appreciable 
risk of GVHD is present at least early after transplantation. immunosup-
pressive therapy is needed. Many patients. however. who successfully en-
graft with donor stem cells become tolerant of the recipient tissues and 
can be completely weaned from immunosuppressive drugs without ad-
verse consequences.3B- 40 
AN OBSERVATION LINKING TWO AREAS OF RESEARCH 
There have been few attempts to confront or reconcile the apparent para-
dox. or dichotomous functions. of donor leukocytes in transplantation bi-
ology:u First. a description was given of how they have been incrimi-
nated as initiators of rejection. and thus deleterious to allograft survival. 
Then. ample evidence has been provided that donor leukocytes can be 
used to induce specific tolerance to an allograft. Few investigators may 
even have recognized that a paradox existed. because it has been widely 
assumed that passenger leukocytes in a solid-organ allograft are funda-
mentally different from bone marrow cells. The former are thought to con-
sist mostly or exclusively of mature cells. such as DCs or mature T cells. 
which have a limited life span. The latter are known to contain a much 
larger fraction of progenitor cells. 
However. one need only to view a few clinical liver allograft biopsies 
with extramedullary hematopoiesis to realize that immature donor cells 
are not infrequently transplanted with an organ. More important. the re-
cent finding that donor leukocytes can survive in recipient tissues for de-
cades after a solid organ allograft42 - 49 certainly invalidates the assump-
tions that passenger leukocytes are terminally differentiated cells or are 
rapidly destroyed. Above all. knowing that donor leukocytes from an al-
lograft organ can survive in the recipient long after transplantation has 
forced us to realize that the role of passenger leukocytes is more complex 
and richer than we had ever imagined. Recently. our laboratories have 
focused considerable attention on the dynamics of passenger leukocyte 
trafficking and survival. 50.51 
As noted earlier. DCs are not the only passenger leukocytes. as com-
monly assumed. There are mature donor T cells that are capable of at-
tacking the host. Mature donor B cells could possibly deliver a tolero-
genic signal. 52 Donor hematolymphoid progenitor cell populations are 
theoretically capable of producing progeny in the recipient. 53 Because 
each organ differs in terms of its profile of passenger leukocytes. the re-
cipient immune system "sees" a different sum total of immunologic 
stimuli with each allograft. How each of these donor cell populations in-
teracts with the recipient immune system when the recipient also is si-
multaneously faced with all of the other donor cell populations certainly 
highlights the complexity involved in transplantation immunology. 
Nevertheless. details of the early emigration patterns of passenger leu-
kocytes from allografts and the participating cell population were recently 
worked out in some detail in experimental small animal models. 50. 51 
Within hours after transplantation leukocytes begin to traffic into and out 
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of the allograft. following hematogenous migratory routes that are inde-
pendent of allogenic barriers.54 - 57 Because of the genetic disparity, how-
ever. donor cells can easily be traced. Donor T and B lymphocytes and 
Des can be found in the splenic marginal zone- periarterial lymphatic 
sheath (PALS) interface and in the PALS a few hours after transplanta-
tion. 50. 51 Within days, they appear in the cortex and then in the paracor-
tex of peripheral. lymph nodes and the thymic medulla. In an allogenic 
environment. both donor and recipient cells begin proliferating50. 51 
within days of mixing with each other. the same as in an MLR in vitro. 
If no immunosuppression is given to the recipient. a brisk prolifera-
tive response develops and the peripheralized donor cells are completely 
destroyed several days before the allograft fails from rejection. 50. 51 If. 
however, the recipient is even transiently immunosuppressed. the prolif-
eration is quieted. but not eliminated. Under the umbrella protection of 
immunosuppression. a month or so after transplantation the donor leu-
kocytes rapidly disseminate to recipient lymphoid tissues and then to ex-
tralymphatic sites such as the skin. intestine. and other visceral organs. 
At these sites. the donor leukocytes come to reside in the same ana-
tomic locations as phenotypically identical recipient counterparts. 50. 51 
For example. donor Des can be found in the thymic medulla and the peri-
arterial lymphatic sheath of the spleen; T cells in the paracortex of lymph 
nodes; B cells in the marginal zone of the spleen; and macro phages and 
Des in the skin. It appears as though a fragment of the donor immune 
system had been transplanted along with the allograft. and had become 
incorporated into the larger network of the recipient.·1t 
If immunosuppressive therapy is withdrawn a month or so after liver 
transplantation in the Lewis (LEW)lbrown Norway rat (BN) strain combi-
nation. the number of donor cells slowly declines to very low levels. But 
even these few cells can survive for up to 200 to 300 days and probably 
for the lifetime of the animals. In humans. donor hematolymphoid cells 
have been detected decades after transplantation.-l 2 - 48 
The number and phenotypic profile of donor cells surviving long-term 
depend to some degree on the source of the donor cells. Murase et a1. 58 
recently showed that BN recipients of LEW liver or bone marrow al-
lografts treated with FK506 for only 4 weeks showed low-level «0.01%) 
multilineage chimerism 100 days later. Heart. kidney. thymocyte. periph-
eral blood. and splenocyte recipients treated in the same fashion were 
devoid of donor cells at this time. Moreover. microchimeric rats accepted 
a subsequent allograft at 100 days from the same donor without immu-
nosuppression. whereas rats devoid of microchimerism eventually re-
jected (some chronically) a subsequent allograft from the same donor. 
Thus the microchimerism after solid organ (liver) transplantation pro-
duced the same results as with the bone marrow. The ability of a liver 
allograft to produce and sustain hematolymphoid microchimerism may. 
in part. explain the resistance of liver allografts to chronic rejection. Per-
sistence of donor cells may also have other effects on the recipient im-
mune system. such as transference of delayed-type hypersensitivity re-
sponsesH . 48 or even resistance to certain diseases. 
The same ends can be accomplished without any immunosuppres-
sion in mice.51 Mouse liver allografts are spontaneously accepted with-
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out immunosuppression and produce long-lived (at least >200 days) mul-
tilineage hematolymphoid chimerism in the recipient. Like the rats that 
were transiently treated. these untreated mice also are able to accept sub-
sequent allografts from the same donor without immunosuppression. Nor-
mally. the extrahepatic organs would be rejected. 
That donor leukocytes can survive in the recipients of solid organ al-
lografts. even after immunosuppressive drugs have been withdrawn. has 
provided the information to reconcile the apparent paradox or dichoto-
mous role of passenger leukocytes in transplantation biology. As de-
scribed earlier. the persistence of hematolymphoid chimerism is associ-
ated with allogenic tolerance; and we have shown that donor hematolym-
phoid cells can persist in the recipients of solid-organ allograft 
recipients.-l2-47.49 Moreover, even human bone marrow allograft recipi-
ents that were thought to be full chimerics still retain a microchimeric 
representation of the recipient-a mirror image of the organ allograft re-
cipients.59.6o We therefore have hypothesized that in principle. hema-
tolymphoid chimerism occurring after solid organ transplantation is the 
same as that observed after bone marrow transplantation.41 . 42 Under both 
circumstances. the hematolymphoid chimerism is responsible for the de-
velopment of subsequent donor-specific acceptance of allograft without 
immunosuppression. Exactly how this happens is currently a matter of 
speculation and the focus of much research. Stimulation of autoreactive 
regulatory cells.41 veto cell mechanism.35 GVH reactivity,47. 48. 61 periph-
eral anergy. and other mechanisms are currently being explored. 
Unfortunately. although hematolymphoid chimerism appears to be a 
necessary condition. alone it is not sufficient for the induction of toler-
ance. 4 1. 42. 45. 47. 48. 61 The final outcome appears to depend on interactions 
between the two different populations of hematolymphoid cells. and 
whether a stable equilibrium between destruction of donor cells and the 
birth of new ones can be achieved. In some instances. the presence of 
donor hematolymphoid cells will spontaneously decrease responsiveness 
of the recipient to the point where immunosuppression is no longer 
needed. In other instances. first the donor leukocytes and eventually the 
allograft would be destroyed without continual immunosuppression. A 
similar situation exists in neonatal mice chimeras.62. 63 In this murine sys-
tem. the stability of chimerism and thus the ability to accept donor al-
lografts is dependent on the strain combinations used. Some are ex-
tremely stable and tolerant of allografts. whereas others have an inher-
ently unstable relationship with donor cells and allografts. They quickly 
reject both when provoked by immunologic stimuli. 
TEST OF A HYPOTHESIS 
The long-term persistence of donor cells; the multilineage character of 
the chimerism: the ability of the bone marrow cell populations to induce 
allograft acceptance without immunosuppression; and the commonality 
of the liver and the bone marrow. all point toward engraftment of a small 
number of progenitor or stem cell popUlations being responsible for the 
microchimerism observed after solid organ transplantation. A major theo-
retical barrier to this hypothesis has apparently been overcome by show-
ing that the dogma of "making space" for bone marrow engraftment by 
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lethal irradiation is probably not valid.53 Thus, besides replacement of 
defective parenchymal cell functions, an allograft brings with it the seeds 
of the donor immune system. Lu et a1.,64 for example, formally showed 
the presence of numerous DC progenitors in the normal mouse liver, and 
other studies, have shown that CD34+ hematolymphoid cells reside in 
normal adult human livers.65 Moreover, progenitor cell populations are 
normally found in the peripheral circulation. It is not too much of a fan-
tasy, therefore, to suggest that progenitor cell populations exist in every 
solid-organ allograft, although clearly, organs like the liver probably have 
a greater complement of such cells. 
If. however, immature passenger leukocytes are beneficial to solid-
organ allograft survival, augmenting the natural emigration out of an al-
lograft by simultaneous infusion of donor bone marrow should ultimately 
result in a greater number of recipients who are eventually drug-free. 
Other protocols mentioned above often rely on delayed infusion. Our aug-
mentation hypothesis is currently being tested at the University of Pitts-
burgh in a group of patients who have undergone either kidney, liver, 
heart. or pancreatic islets transplantation with the simultaneous infusion 
of 3 x 108 cells/kg body weight of unfractionated donor bone marrow.6f!. 
These recipients were not preconditioned in any way and no antilym-
phocyte globulin induction therapy was used. Instead, they received the 
standard two-drug immunosuppressive cocktail of FK506 and steroids. 
The patients are currently being prospectively followed for the presence 
of hematolymphoid chimerism, graft rejection, and in vitro evidence of 
donor-specific alloreactivity. The results to date are shown in Tables 1 
and 2. 
At this time, it is too early to determine whether our hypothesis is 
correct. but several points have become clear. In contrast to small experi-
mental animal models. the presence of hematolymphoid chimerism is not 
synonymous with protection from rejection or GVHD. particularly in the 
early posttransplant period. Both serious rejection reactions and minor 
GVHD have occurred in this population, simultaneously, with the detec-
tion of peripheral blood chimerism. Secondly, infusion of donor bone 
marrow under the conditions employed is relatively safe. It does not ap-
pear to result in increased or unmanageable rejection. Moreover, stable 
hematolymphoid chimerism has been observed for as long as 14 months 
after transplantation (the longest patient follow-up), all without prior con-
ditioning of the recipient. The degree of chimerism in patients with peri-
operative bone marrow augmentation is orders of magnitude greater than 
that observed after solid organ transplantation alone.66 
The aim of the aforementioned protocol is to reduce the number of 
patients who require lifelong nonspecific immunosuppression after solid-
organ transplantation. Drug-free allograft acceptance and freedom from 
GVHD for everyone who receives an allograft with bone marrow augmen-
tation is an unreasonable expectation. The potential benefits will be long-
term and likely will be dictated by the genetic constitution of the recipi-
ent and donor similar to the strain dependency observed in small animal 
models. It is unlikelv, however, that compatibility will segregate along 
the lines of classic MHC matching currently pursued in clinical trans-
plantation. 
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